Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric anifrolumab placebo-controlled phase 3 study in active systemic lupus erythematosus
2022-502289-25-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Anifrolumab plus background standard of care with Placebo plus background standard of care (2 arms). Primary endpoints: Pharmacokinetics after single dose or dose adjustment and BICLA response at Week 52. Planned start Nov 2023; status: authorised.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2022-502289-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502289-25-00.